Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review
Author:
Funder
Daiichi Sankyo Inc
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10549-021-06469-0.pdf
Reference20 articles.
1. Goddard KA, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C (2012) HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics 15(1):1–10
2. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju055
3. Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177(2):237–250
4. Asif HM, Sultana S, Ahmed S, Akhtar N, Tariq M (2016) HER-2 positive breast cancer—a mini-review. Asian Pac J Cancer Prev 17(4):1609–1615
5. Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C et al (2020) Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat 183(1):23–39
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Case report: Urothelial injury in a female with breast cancer: a rare adverse event after the combination of paclitaxel and trastuzumab;Frontiers in Oncology;2024-01-18
2. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives;Nature Reviews Clinical Oncology;2024-01-08
3. Modified pectin with anticancer activity in breast cancer: A systematic review;International Journal of Biological Macromolecules;2024-01
4. Early Recognition and Management of Side Effects Related to Systemic Anticancer Therapy for Advanced Breast Cancer;Seminars in Oncology Nursing;2024-01
5. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis;JNCI Cancer Spectrum;2023-08-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3